glp 1 agonist anesthesia GLP-1 Receptor Agonists and Gastrointestinal Endoscopy: A Narrative Review of Risks, Management Strategies, and the Need for Clinical Consensus Patients may consider GLP-1 agonist

Description

While the FDA recently approved the first generic version of Victoza , or liraglutidea first-generation GLP-1 that has been on the FDA's shortage list since 2023demand for the once-daily injection has waned as patients move to more effective once-weekly treatments like Ozempic and Mounjaro

The REWIND trial mainly assessed the cardiovascular outcomes of dulaglutide over up to 8 years

Such interest could result in GLP-1 penetration reaching nearly 20% of the US adult population within two years, and the pill format could expand the active GLP-1 user population by as much as 50% by 2027, according to Big Chalk

Overall prescribing rates (GLP-1 RA prescriptions per total prescriptions) in December 2025 increased slightly relative to September 2025 (+5.0%) and now account for more than 7% of all prescriptions